The Patent Finder

Idec Pharmaceuticals Corp. (Delaware)

Also on record
Records under this name other than patents Idec Pharmaceuticals Corp. (Delaware) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 8 of 8 · Back to Idec Pharmaceuticals Corp. (Delaware)

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 6,682,734Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Formerly held
Term ended
Ended no later than Jan 27, 2021 · USPTO record
Term endedEnded no later than Jan 27, 2021USPTO record
US 7,744,877Expression and use of anti-CD20 Antibodies
Formerly held
Term ended
Term ended Jun 21, 2019 · USPTO record
Term endedTerm ended Jun 21, 2019USPTO record
US 6,399,061Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
Formerly held
Term ended
Term ended Jun 4, 2019 · USPTO record
Term endedTerm ended Jun 4, 2019USPTO record
US 7,381,560Expression and use of anti-CD20 antibodies
Formerly held
Term ended
Term ended Sep 22, 2016 · USPTO record
Term endedTerm ended Sep 22, 2016USPTO record
US 7,422,739Anti-CD20 antibodies
Formerly held
Term ended
Term ended Sep 3, 2015 · USPTO record
Term endedTerm ended Sep 3, 2015USPTO record
US 5,736,137Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Formerly held
Term ended
Term ended no later than Apr 7, 2018 · Low confidence
Term endedTerm ended no later than Apr 7, 2018Low confidence
US 5,776,456Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Formerly held
Term ended
Term ended no later than Jul 7, 2018 · Low confidence
Term endedTerm ended no later than Jul 7, 2018Low confidence
US 5,843,439Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Formerly held
Term ended
Term ended no later than Dec 1, 2018 · Low confidence
Term endedTerm ended no later than Dec 1, 2018Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited